光正眼科控股股东股份被冻结，2025年业绩预告大幅减亏

Group 1: Shareholder Pledge and Control - The controlling shareholder, Guangzheng Investment, has had 9.15 million shares frozen, accounting for 7.08% of its holdings and 1.78% of the company's total share capital. The freeze period is from January 30, 2026, to January 29, 2029. The company states this will not lead to a change in control and will not have a substantial impact on operations [2]. Group 2: Financial Performance - The company expects a net profit attributable to shareholders for 2025 to be between -5 million and -3 million yuan, indicating a significant reduction in losses of 97.14% to 98.28% compared to a loss of 175 million yuan in the same period of 2024. This improvement is attributed to lean operations in the medical sector, cost control, and a significant reduction in goodwill impairment [3]. Group 3: Related Party Transactions - The company’s board approved a total of up to 15 million yuan for daily related party transactions with Guangzheng Yanyuan Health Management Co., Ltd. and its subsidiaries for the year 2026 [4]. Group 4: Management Changes - A new senior management team has been appointed, including positions such as Vice President, Chief Financial Officer, and Board Secretary, as of December 28, 2025 [5]. Group 5: Business Development - The company has increased its investment in ophthalmology by acquiring, establishing, and holding stakes in multiple ophthalmology-related companies throughout 2025 [6].